BrainChild Bio raises $116M Series A to fund Phase 2 CAR‑T trial for pediatric diffuse intrinsic pontine glioma

BrainChild Bio raised $116 million in Series A financing to advance CAR-T therapies into the central nervous system, funding a Phase 2 trial of its lead candidate for pediatric diffuse intrinsic pontine glioma while planning future adult indications.

More: FinSMEs, Endpoints News, Fierce Biotech, BioSpace, GEN - Genetic Engineering and Biotechnology News, GeekWire, WebProNews, BrainChild Bio, Inc.
Comments: Kyle LaHucik, Alex Philippidis

No comments yet.